PD-1 Blockade With SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma:an Open-label Phase I/II Trial
Phase of Trial: Phase I/II
Latest Information Update: 08 Oct 2018
At a glance
- Drugs Camrelizumab (Primary) ; Decitabine (Primary)
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 28 Sep 2018 Planned number of patients changed from 40 to 150.
- 28 Sep 2018 Primary endpoint has changed from ORR to CRR.
- 28 Sep 2018 Planned End Date changed from 21 Mar 2019 to 21 Mar 2020.